Zobrazeno 1 - 10
of 443
pro vyhledávání: '"M. Reith"'
Publikováno v:
Journal of Primary Health Care, Vol 12, Iss 4, Pp 327-334 (2020)
ABSTRACT INTRODUCTIONDabigatran etexilate has become widely used in New Zealand, but information relating to when renal function monitoring is being undertaken is lacking. AIMTo investigate if clinically appropriate renal function monitoring is being
Externí odkaz:
https://doaj.org/article/13a61cca7271446fb7d8bfde50b40439
Autor:
Ruirui Dong, Razik Mu-u-min, Alastair J. M. Reith, Christopher O’Shea, Shicheng He, Kaizhong Duan, Kun Kou, Alexander Grassam-Rowe, Xiaoqiu Tan, Davor Pavlovic, Xianhong Ou, Ming Lei
Publikováno v:
Frontiers in Physiology, Vol 10 (2019)
Among the animal models for studying the molecular basis of atrial and sinoatrial node (SAN) biology and disease, the mouse is a widely used species due to its feasibility for genetic modifications in genes encoding ion channels or calcium handling a
Externí odkaz:
https://doaj.org/article/4eda4a1343e84d108df68cd11554f4b7
Publikováno v:
TH Open, Vol 03, Iss 03, Pp e210-e215 (2019)
Abstract Background Dabigatran etexilate has become widely used for the prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF). Currently, there is limited information in real-world patients relating to dabigatran etexilate ex
Externí odkaz:
https://doaj.org/article/9fae1b536eac4845a8091b5dd27cb35f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Malihah Burke, Helen Bernhardt, David M. Reith, David Barker, Roland S. Broadbent, Benjamin J. Wheeler
Publikováno v:
Australian and New Zealand Journal of Public Health, Vol 39, Iss 6, Pp 573-576 (2015)
Abstract Objectives: To describe rates of newborn vitamin K prophylaxis uptake according to method of administration (intramuscular [IM], oral, refused) and identify predictors for the choice of oral administration and for refusal of vitamin K prophy
Externí odkaz:
https://doaj.org/article/57a81051bb514edd99a18e77f737bab0
Publikováno v:
TH Open, Vol 02, Iss 04, Pp e420-e427 (2018)
Abstract Background Clinical significance of dosing dabigatran with different estimates of renal function for treatment of atrial fibrillation (AF) is unknown. Renal function is routinely estimated by the chronic kidney disease epidemiology initiat
Externí odkaz:
https://doaj.org/article/6d784366612745f491ff0d8f327a63a5
Autor:
Lisa Jean Kremer, Natalie Medlicott, Mary Jane Sime, Roland Broadbent, Liza Edmonds, Mary Judith Berry, Nicola C Austin, Jane M Alsweiler, David M Reith
Publikováno v:
Archives of disease in childhood. Fetal and neonatal edition.
ObjectiveTo determine if very low dose (VLD, 0.5% phenylephrine, 0.1% cyclopentolate) mydriatic microdrop (approximately 7 μL) administration (up to three doses) is non-inferior to low dose (LD, 1% phenylephrine, 0.2% cyclopentolate) mydriatic micro
Autor:
David M. Reith, Martyn Williamson, Alesha Smith, Sharon Leitch, Steven Lillis, Wayne Cunningham, Katharine Wallis, Andrew W. McMenamin, Kyle Eggleton, Jiaxu Zeng, Susan Dovey
Publikováno v:
The British Journal of General Practice
BackgroundThe extent of medication-related harm in general practice is unknown.AimTo identify and describe all medication-related harm in electronic general practice records. The secondary aim was to investigate factors potentially associated with me
Autor:
Roland S. Broadbent, Liza Edmonds, Natalie J. Medlicott, Mary Jane Sime, David M. Reith, Lisa Kremer
Publikováno v:
American Journal of Perinatology. 39:1779-1785
This study was aimed to determine mydriatic regimen(s) used in neonatal units in Aotearoa, New Zealand (NZ), and Australia and to estimate the frequency of adverse drug events following mydriatic administration in preterm neonates. A cross-sectional
Autor:
Frances McCaffrey, Mary Jane Sime, David M. Reith, Roland S. Broadbent, Lisa Kremer, Natalie J. Medlicott
Publikováno v:
Archives of Disease in Childhood. 106:603-608
AimsTo determine ifVery low dose mydriatic eye microdrop regimen sufficiently dilates the pupil (above 4.1 mm) compared with the currently used low dose mydriatic eye microdrop regimen.Cardiovascular, gastrointestinal and respiratory adverse effects